[{"id":"1eb7a494-8bc2-4917-8b85-cf6852752fd9","acronym":"GLORIA","url":"https://clinicaltrials.gov/study/NCT04121455","created_at":"2021-03-03T18:53:40.301Z","updated_at":"2024-07-02T16:35:45.144Z","phase":"Phase 1/2","brief_title":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","source_id_and_acronym":"NCT04121455 - GLORIA","lead_sponsor":"TME Pharma AG","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • olaptesed pegol (NOX-A12)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-06-22"},{"id":"834f7878-f144-4132-a7c5-5d5bcd1de5e0","acronym":"Keynote-559","url":"https://clinicaltrials.gov/study/NCT03168139","created_at":"2021-01-18T15:37:14.845Z","updated_at":"2025-02-25T16:06:18.896Z","phase":"Phase 1/2","brief_title":"Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer","source_id_and_acronym":"NCT03168139 - Keynote-559","lead_sponsor":"TME Pharma AG","biomarkers":" CXCL12","pipe":"","alterations":" ","tags":["CXCL12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • olaptesed pegol (NOX-A12)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 03/25/2020","primary_completion_date":" 03/25/2020","study_txt":" Completion: 03/25/2020","study_completion_date":" 03/25/2020","last_update_posted":"2020-07-08"}]